Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Effects of natalizumab treatment on the CSF proteome of multiple sclerosis patients.
Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis.
Effects of dalfampridine on multi-dimensional aspects of gait and dexterity in multiple sclerosis among timed walk responders and non-responders.
Unprovoked seizures in multiple sclerosis and systemic lupus erythematosus: A population-based case-control study.
Detecting cortical lesions in multiple sclerosis at 7 T using white matter signal attenuation.
Minocycline treatment for rheumatoid arthritis: an open dose finding study.
Evidence-based guideline: Assessment and management of psychiatric disorders in individuals with MS: Report of the Guideline Development Subcommittee of the American Academy of Neurology.
Phase IV Study Reports Multiple Sclerosis Success with Teriflunomide
The little compound that could: how phenytoin changed drug discovery and development.
GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40mg three-times weekly versus 20mg daily in patients with relapsing-remitting multiple sclerosis.
The Impact of Lesion In-Painting and Registration Methods on Voxel-Based Morphometry in Detecting Regional Cerebral Gray Matter Atrophy in Multiple Sclerosis.
Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis.
Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis.
Treatment of walking impairment in multiple sclerosis with dalfampridine.
Transcriptomics: mRNA and alternative splicing.
Do positive or negative stressful events predict the development of new brain lesions in people with multiple sclerosis?
The influence of HLA-DRB1*15 on motor cortical pathology in multiple sclerosis.
The investigation of acute optic neuritis: a review and proposed protocol.
Synthon obtains approval for glatiramer acetate 20 mg/mL in Europe
Food and Drug Administration briefing document for ofatumumab
Tysabri
Metabolomics of cerebrospinal fluid reveals changes in the central nervous system metabolism in a rat model of multiple sclerosis.
High-field imaging of neurodegenerative diseases.
Santhera receives first product approval: Health Canada approves Catena® for treatment of Friedreich's ataxia

Pages